Lisata Therapeutics Stock Probability of Future Stock Price Finishing Under 2.77

LSTA Stock  USD 2.62  0.20  7.09%   
Lisata Therapeutics' future price is the expected price of Lisata Therapeutics instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Lisata Therapeutics performance during a given time horizon utilizing its historical volatility. Check out Lisata Therapeutics Backtesting, Lisata Therapeutics Valuation, Lisata Therapeutics Correlation, Lisata Therapeutics Hype Analysis, Lisata Therapeutics Volatility, Lisata Therapeutics History as well as Lisata Therapeutics Performance.
For information on how to trade Lisata Stock refer to our How to Trade Lisata Stock guide.
  
At present, Lisata Therapeutics' Price To Sales Ratio is projected to drop slightly based on the last few years of reporting. The current year's Price Book Value Ratio is expected to grow to 0.48, whereas Price Earnings Ratio is forecasted to decline to (1.11). Please specify Lisata Therapeutics' target price for which you would like Lisata Therapeutics odds to be computed.

Lisata Therapeutics Target Price Odds to finish below 2.77

The tendency of Lisata Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to stay under $ 2.77  after 90 days
 2.62 90 days 2.77 
about 12.03
Based on a normal probability distribution, the odds of Lisata Therapeutics to stay under $ 2.77  after 90 days from now is about 12.03 (This Lisata Therapeutics probability density function shows the probability of Lisata Stock to fall within a particular range of prices over 90 days) . Probability of Lisata Therapeutics price to stay between its current price of $ 2.62  and $ 2.77  at the end of the 90-day period is about 11.38 .
Given the investment horizon of 90 days Lisata Therapeutics has a beta of 0.56. This indicates as returns on the market go up, Lisata Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Lisata Therapeutics will be expected to be much smaller as well. Additionally Lisata Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Lisata Therapeutics Price Density   
       Price  

Predictive Modules for Lisata Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Lisata Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Lisata Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.132.635.75
Details
Intrinsic
Valuation
LowRealHigh
1.844.968.08
Details
Naive
Forecast
LowNextHigh
0.052.625.74
Details
2 Analysts
Consensus
LowTargetHigh
10.7711.8313.13
Details

Lisata Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Lisata Therapeutics is not an exception. The market had few large corrections towards the Lisata Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Lisata Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Lisata Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.14
β
Beta against Dow Jones0.56
σ
Overall volatility
0.12
Ir
Information ratio -0.06

Lisata Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Lisata Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Lisata Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Lisata Therapeutics generated a negative expected return over the last 90 days
Lisata Therapeutics has high historical volatility and very poor performance
Net Loss for the year was (20.84 M) with profit before overhead, payroll, taxes, and interest of 0.
Lisata Therapeutics currently holds about 72.99 M in cash with (20.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 18.07, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 19.0% of the company outstanding shares are owned by corporate insiders
Latest headline from investing.com: Castle Biosciences CEO Derek Maetzold sells 160,741 in shares

Lisata Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Lisata Stock often depends not only on the future outlook of the current and potential Lisata Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Lisata Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding8.1 M
Cash And Short Term Investments50.5 M

Lisata Therapeutics Technical Analysis

Lisata Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Lisata Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Lisata Therapeutics. In general, you should focus on analyzing Lisata Stock price patterns and their correlations with different microeconomic environments and drivers.

Lisata Therapeutics Predictive Forecast Models

Lisata Therapeutics' time-series forecasting models is one of many Lisata Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Lisata Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Lisata Therapeutics

Checking the ongoing alerts about Lisata Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Lisata Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Lisata Therapeutics generated a negative expected return over the last 90 days
Lisata Therapeutics has high historical volatility and very poor performance
Net Loss for the year was (20.84 M) with profit before overhead, payroll, taxes, and interest of 0.
Lisata Therapeutics currently holds about 72.99 M in cash with (20.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 18.07, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 19.0% of the company outstanding shares are owned by corporate insiders
Latest headline from investing.com: Castle Biosciences CEO Derek Maetzold sells 160,741 in shares
When determining whether Lisata Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lisata Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lisata Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lisata Therapeutics Stock:
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lisata Therapeutics. If investors know Lisata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lisata Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.51)
Return On Assets
(0.29)
Return On Equity
(0.44)
The market value of Lisata Therapeutics is measured differently than its book value, which is the value of Lisata that is recorded on the company's balance sheet. Investors also form their own opinion of Lisata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Lisata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lisata Therapeutics' market value can be influenced by many factors that don't directly affect Lisata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lisata Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lisata Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lisata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.